)
Medistim (MEDI) investor relations material
Medistim Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue reached a record NOK 210m, up 25.9% reported and 31.5% currency-neutral; own-product sales rose 34.6% currency-neutral.
YTD revenue reached a record NOK 613.7m, up 18.6% reported and 23.6% currency-neutral; own-product sales grew 30.1% currency-neutral.
Q3 EBIT rose 55.7% to NOK 63.1m; YTD EBIT increased 20.6% to NOK 185.5m.
Financial highlights
Q3 gross margin improved to 84.5% from 81.5%; strong sales and favorable mix supported the increase, alongside a NOK 2.7m net tariff expense.
Q3 EBITDA was NOK 70.6m; profit after tax was NOK 47.8m versus NOK 34.7m, and EPS was NOK 2.61 versus NOK 1.90.
YTD EBITDA reached NOK 205.2m versus NOK 171.7m; profit after tax was NOK 140.3m versus NOK 121.1m, and EPS was NOK 7.67 versus NOK 6.63.
Q3 operating cash flow was NOK 91.5m; YTD operating cash flow was NOK 146.5m, with working capital weighing on the YTD figure.
Segment performance
AMERICAS Q3 revenue was NOK 116.9m, up 51.7% currency-neutral, driven by Flow-and-Imaging systems and imaging probes; the U.S. generated ~95% of regional revenue.
APAC Q3 revenue was NOK 33.6m, up 44.6% currency-neutral; China and Japan grew, while distributor sales can vary by quarter.
EMEA Q3 revenue was NOK 36.9m, up 5.5% currency-neutral; direct markets grew while distributor sales declined 17.5%.
Q3 Cardiac sales rose 35.0% to NOK 161.6m; Vascular sales were NOK 25.9m, essentially flat. Imaging sales grew 57.9% to NOK 72.7m and Flow sales rose 15.4% to NOK 114.9m.
Flow-and-Imaging system unit sales increased 27%; Flow-only system units rose 22%, Flow probe units grew 8.7%, and imaging probe units rose 30% in AMERICAS.
- Record sales, high margins, and robust recurring revenue drive upgraded growth outlook.MEDI
Q2 2026 - Record revenue and strong margins driven by APAC growth and direct sales expansion.MEDI
Q1 2026 - Record revenue and EBIT growth, strong cash, and NOK 8.00 dividend proposed for 2025.MEDI
Q4 2025 - Record H1 sales and profit growth, led by Americas, APAC, and new product launches.MEDI
Q2 2025 - Growth to NOK 1 billion targeted via INTUI software, innovation, and global clinical validation.MEDI
CMD 2024 - Q3 revenue up 7%, EBIT margin at 24%, strong Americas, and recurring sales at 73–75%.MEDI
Q3 2024 - Record Q2 sales, margin recovery, and EMEA growth offset APAC headwinds.MEDI
Q2 2024 - Record Q1 with 35.7% revenue growth, 84.5% EBIT surge, and strong outlook as INTUI launches.MEDI
Q1 2025 - Record sales, stable profit, and new innovations set up for strong 2025 growth.MEDI
Q4 2024
Next Medistim earnings date
Next Medistim earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)